Zoetis Shares Fall Despite $160M Neogen Unit Acquisition

Deal at a Glance

Zoetis announced it will acquire Neogen Corporation’s animal genomics business for $160 million. Despite the strategic move, Zoetis shares fell 1.55% following the announcement.

Strategic Overview

The transaction grants Zoetis access to Neogen's genetic testing technologies and data tools designed to predict animal health outcomes. According to BofA analysts, Neogen had signaled its intention to divest the underperforming genomics business to streamline its portfolio and concentrate on its core Animal Safety markets.

Market Impact and Analysis

Leerink analysts commented that while the deal is not a significant financial driver, it is strategically sound. It modestly bolsters Zoetis's livestock focus, particularly in the cattle sector which accounts for about 55% of the acquired business's revenue. This increases the company's exposure to a strong-performing end market.

Concluding Outlook

The acquisition allows Zoetis to enhance its genomics capabilities while enabling Neogen to focus on more profitable areas. The market's initial negative reaction to the news may not reflect the long-term strategic benefits of the deal for Zoetis.

FAQ

Q: Why did Zoetis acquire this Neogen business?
A: To strengthen its livestock operations and gain access to predictive genetic testing technologies for better animal care.

Q: How did Zoetis stock react to the news?
A: Zoetis shares fell 1.55% on the day of the announcement.

Source: Investing.com